CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision

• Status: Completed
• Trial end date: 2007-11-01

Summary

Primary objective:

• Pathological complete response (ypT0N0) rate

Secondary objectives:

• Histopathological R0 resection rate

• Pathological downstaging (ypT0-T2N0) rate

• One month surgical complication rate

• Predictive value of pre-operative MRI for surgical, pathological and clinical outcomes

• Safety

• Local and distant recurrence rates

• Progression-free survival

• Overall survival

• Phase: Phase 2

Details

• Lead Sponsor: Sanofi
• Treatments: Capecitabine; Oxaliplatin